Navigation Links
BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
Date:4/22/2008

FDA agrees to first SPA for an oncolytic product

WOBURN, Mass., April 22 /PRNewswire/ -- BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX(GM-CSF) in previously treated patients with metastatic melanoma. The agreement was made under the Special Protocol Assessment (SPA) procedure.

BioVex is currently concluding a 50-patient Phase II trial for OncoVEX(GM-CSF) as stand alone therapy in patients with unresectable Stage IIIc and Stage IV metastatic melanoma. The trial was designed to measure overall objective response, which is defined as a complete response (CR), where disease is completely eliminated, or partial response (PR), where there is a >30% reduction in disease burden. Interim results from the study demonstrated a highly encouraging rate of durable objective response with multiple patients with metastatic disease at enrollment having been declared disease free following therapy. The full study has been accepted for oral presentation at ASCO on June 1st where the results will be presented.

The Phase III study design agreed with the FDA follows directly from the study design successfully employed in Phase II. The Phase III study will also enroll previously treated patients with unresectable stage IIIc and stage IV disease using OncoVEX(GM-CSF) as monotherapy. The primary efficacy endpoint will also be response rate-based; the primary objective being to demonstrate a statistically significant increase in the rate of objective responses maintained for six months or more, in comparison to control therapy (subcutaneously administered(GM-CSF). The study is intended to enroll 360 evaluable patients randomized such that 240 patients receive OncoVEX(GM-CSF) and 120 patients receive control.

The pivotal study is expected to commence in the first quarter of 2009, with a potential projected BLA filing in late 2010. BioVex is currently commissioning its GMP manufacturing facility in Woburn, Massachusetts, which is intended to provide product for Phase III studies and launch.

Dr Robert Coffin, Chief Technology Officer for BioVex, said:

"This agreement with the FDA for the pivotal Phase III study design for OncoVEX(GM-CSF) in melanoma, which uses a very similar design as successfully employed in Phase II, is a significant event for BioVex. We believe the Phase II study results relating to durable objective response provide a sound basis on which to proceed with confidence to Phase III where the primary objective is to demonstrate a statistically significant increase in durable objective responses as compared to control therapy. We look forward to the presentation of the Phase II results at ASCO, and thereafter to the initiation of the pivotal study."

About BioVex

BioVex is a privately held biotechnology Company based in Woburn, MA. The Company is developing a new class of potent biologics for the treatment of cancer and prevention of infectious disease.

The Company's lead cancer technology platform, OncoVEX(GM-CSF), is an unpartnered, first-in-class oncolytic, or cancer destroying virus technology. OncoVEX(GM-CSF) works by: 1) replicating and spreading within solid tumors, causing the death of cancer cells; while 2) stimulating the immune system to destroy metastatic deposits. Both modes of action have been clearly validated in the clinic, where multiple patients with metastatic disease progressing at enrollment have been declared disease free. Based on the strength of the clinical data generated to date, coupled with a benign side effect profile, BioVex believes OncoVEX(GM-CSF) has the potential to become a leading standard of care in the treatment of many solid tumors.

OncoVEX(GM-CSF) is currently completing a Phase II clinical trial for melanoma and Phase I/II clinical trials for head & neck cancer and pancreatic cancer.

The Company's second program is a vaccine for genital herpes, ImmunoVEX HSV2, which provides complete protection in animal models of the disease. A Phase I study with ImmunoVEX HSV2 is scheduled to initiate later this year.

For more information visit the company's website at http://www.biovex.com.


'/>"/>
SOURCE BioVex Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Arpida Provides Further Comments on the Pivotal Phase III Trials
2. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
3. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
6. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
7. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
10. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
11. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson ... offers insurance and financial preparation services, is providing an update on a charitable ... , Rock City Rescue is a locally recognized nonprofit that provides shelter and ...
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health ... technology. Applying the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing ... form that can be easily incorporated into liquid products, while reducing costs to end ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... VA (PRWEB) , ... October 13, 2017 , ... ... of DevOps and Agile Software Development, has been awarded a contract by the ... Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
Breaking Medicine News(10 mins):